Looking for Ofev follow-up, Boehringer picks up Bridge Biotherapeutics' IPF med for $50M

Nearly five years after lung-scarring med Ofev got the FDA nod, its maker wants to get cracking on a  successor. Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million ($50 million) upfront.